Press Release

Epinephrine Auto-Injector Market is predicted to worth $6.21 billion in 2026

September, 2020

" COVID-19 impact on Epinephrine Auto-Injector Market Share, Size, global opportunities, and industry forecast, 2019-2026 "

Epinephrine Autoinjectors are the medical devices that are used to treat anaphylaxis by monitoring and doses of adrenaline or epinephrine. These are handheld devices, which contain a fixed epinephrine dose and a spring-loaded needle to inject the medicine to the patients suffering from anaphylaxis or severe allergic reactions.

The growth of the epinephrine auto-injector market is backed by the increasing allergy incidences, rise in awareness about the allergies, and technological developments in the R&D activities such as rising demand for auto-injectors over the conventional devices and chlorofluorocarbon (CFC) free epinephrine auto-injector inhalers using hydrofluoroalkane propellants. High costs and regulatory hurdles are limiting the growth of this market.

The global epinephrine auto-injector market segmentations have been created on the basis of region, end-user, dosage, and age group. The market segmentation based on dosage is 0.15 mg, 0.3 mg, and others. Based on age, the market is divided into – up to 4 years, 5-14 years, 15-24 years, 25-49 years, 50-64 years, and above 65 years categories. Geographically the market is segmented into Europe, Asia Pacific, LAMEA, and North America. Whereas, based on end-users, the market is segmented into clinics, hospitals, and individuals.

Request for sample report @

The global report titled “Epinephrine Autoinjector Market by age group, by region, by Dosage, and by End-user – Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2026” provides valuable insights about the current and the future trends in this market. This report helps in determining the future opportunities in this market.

The key companies operating in this market are Teva Pharmaceutical Industries Ltd., Antares Pharma, ALK-Abell A/S, Adamis Pharmaceuticals Corporation, Lincoln Medical Centre Ltd., Mylan N.V., Impax Laboratories, Inc., Pfizer Inc., Bausch & Lomb Incorporated, and Kaleo, Inc. this report also analyses these companies’ strategies to understand the competitive outlook of this market.

Access full report summary @

The segmentation of the auto-injector market is as follows:

On the basis of the End-User: -

  • Hospitals
  • Clinics
  • Home Based
  • Others

On the basis of the dosage: -

  • 0.15 mg
  • 0.3 mg
  • Others

On the basis of the Age Group: -

  • 0-4 Years
  • 5-14 Years
  • 15-24 Years
  • 25-49 Years
  • 50-64 Years
  • Above 65 Years

On the basis of geography: -

  • North America
  • Asia pacific
  • Europe
  • Rest of World

Mr. Karthick Subramani

Infoholic Research LLP

Marketing & Communication